Likely for URTI and when they develop into LRTI/pneumonia, then consumers use ResAppDx with a clinician but if pharmacist can be classified as clinician, I can see RB being interested in ResAppDx as well. But I still think RB (like Sanofi) are interested in chronic respiratory management for asthma and COPD.
